Abstract
Mycobacteria, especially M. tuberculosis, have remained a worldwide dominant cause for human morbidity (∼10 million annual cases) and mortality (3 million deaths annually) since ancient times. An estimated one-third of living humans are latently infected with M. tuberculosis. Despite this, there have been no new drugs specifically developed against mycobacteria since the 1960s. Because of a slow growth rate, biosafety concerns, and other issues, drug discovery by in vitro screening of natural and synthetic compounds has been limited in the past. However, a number of new techniques and technologies for whole cell antimycobacterial screening have been developed recently. This review examines and compares these methods, discusses common issues in screening with mycobacteria, and considers potential future developments in the field.
Keywords: Mycobacterium, drug discovery, resazurin, alamar blue, nitrate reductase, luciferase, green fluorescent protein
Current Bioactive Compounds
Title: Recent Advances in Methodologies for the Discovery of Antimycobacterial Drugs
Volume: 3 Issue: 3
Author(s): Todd P. Primm and Scott G. Franzblau
Affiliation:
Keywords: Mycobacterium, drug discovery, resazurin, alamar blue, nitrate reductase, luciferase, green fluorescent protein
Abstract: Mycobacteria, especially M. tuberculosis, have remained a worldwide dominant cause for human morbidity (∼10 million annual cases) and mortality (3 million deaths annually) since ancient times. An estimated one-third of living humans are latently infected with M. tuberculosis. Despite this, there have been no new drugs specifically developed against mycobacteria since the 1960s. Because of a slow growth rate, biosafety concerns, and other issues, drug discovery by in vitro screening of natural and synthetic compounds has been limited in the past. However, a number of new techniques and technologies for whole cell antimycobacterial screening have been developed recently. This review examines and compares these methods, discusses common issues in screening with mycobacteria, and considers potential future developments in the field.
Export Options
About this article
Cite this article as:
Primm P. Todd and Franzblau G. Scott, Recent Advances in Methodologies for the Discovery of Antimycobacterial Drugs, Current Bioactive Compounds 2007; 3 (3) . https://dx.doi.org/10.2174/157340707781695550
DOI https://dx.doi.org/10.2174/157340707781695550 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vaccine Delivery - Current Trends and Future
Current Drug Delivery Synthesis of Isoxazole Moiety Containing Thieno[2,3-d]pyrimidine Derivatives and Preliminarily in vitro Anticancer Activity (Part II)
Anti-Cancer Agents in Medicinal Chemistry Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Association of the Clinico-Demographic and Laboratory Profile with Treatment Outcomes in Patients with Drug-Resistant Pulmonary Tuberculosis
Current Respiratory Medicine Reviews Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Ethnobotanical Bioprospection of Candidates for Potential Antimicrobial Drugs from Brazilian Plants: State of Art and Perspectives
Current Protein & Peptide Science The β and γ Classes of Carbonic Anhydrase
Current Pharmaceutical Design 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study
Current Topics in Medicinal Chemistry IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition Structure and Regulation of the Drug-Metabolizing Enzymes Arylamine N-acetyltransferases
Current Medicinal Chemistry Design and Synthesis of Some Newer Pyrimidine Hydroxamates as Histone Deacetylase Inhibitors
Current Enzyme Inhibition Penicillium marneffei and its Pulmonary Involvements
Current Respiratory Medicine Reviews Recent Advancements in 1,4-Disubstituted 1H-1,2,3-Triazoles as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Editorial [ Carbonic Anhydrases as Drug Targets Executive Editor: Claudiu T. Supuran ]
Current Pharmaceutical Design Multiple-Dose Pharmacokinetics of Efavirenz with and without the Use of Rifampicin in HIV-Positive Patients
Current HIV Research Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design State of the Art in African Trypanosome Drug Discovery
Current Topics in Medicinal Chemistry The Impact of Crystallographic Data for the Development of Machine Learning Models to Predict Protein-Ligand Binding Affinity
Current Medicinal Chemistry Preface [Hot Topic: Antimycobacterial Drugs: Current Status and Future Prospects (Executive Editor: Haruaki Tomioka)]
Current Pharmaceutical Design